. Antithrombotictrialists-'collaboration, Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocarfial infarction, and stroke in high-risk patients, BMJ, vol.324, pp.71-86, 2002.

C. Patrono, B. Coller, G. Fitzgerald, J. Hirsh, and G. Roth, Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects, Chest, vol.126, issue.3, pp.234-64, 2004.
DOI : 10.1378/chest.126.3_suppl.234S

T. Cuisset, C. Frere, J. Quilici, B. Gaborit, and L. Bali, Aspirin noncompliance is the major cause of ???aspirin resistance??? in patients undergoing coronary stenting, American Heart Journal, vol.157, issue.5, pp.889-93, 2009.
DOI : 10.1016/j.ahj.2009.02.013

M. Call, M. Tedesco, A. Peace, A. Foley, D. Cox et al., Aspirin resistance; an investigation and explanation, J Thromb Heamost, vol.7, pp.2-572, 2009.

K. Schwartz, D. Schwartz, K. Ghosheh, M. Reeves, and K. Barber, Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction, The American Journal of Cardiology, vol.95, issue.8, pp.973-975, 2005.
DOI : 10.1016/j.amjcard.2004.12.038

G. Cotter, E. Shemesh, M. Zehvzi, I. Dinur, and A. Rudnick, Lack of aspirin effect: aspirin resistance or resistance to taking aspirin?, American Heart Journal, vol.147, issue.2, pp.293-300, 2004.
DOI : 10.1016/j.ahj.2003.07.011

K. Schwartz, D. Schwartz, K. Barber, M. Reeves, D. Franco et al., Non-compliance is the predominant cause of aspirin resistance in chronic coronary arterial disease patients, Journal of Translational Medicine, vol.6, issue.1, p.46, 2008.
DOI : 10.1186/1479-5876-6-46

G. Krasopoulos, S. Brister, and W. Beattie, Aspirin ???resistance??? and risk of cardiovascular morbidity: systematic review and meta-analysis, BMJ, vol.336, issue.7637, pp.195-210, 2008.
DOI : 10.1136/bmj.39430.529549.BE

. C. Patrono, Aspirin resistance: definition, mechanisms and clinical read-outs, Journal of Thrombosis and Haemostasis, vol.73, issue.8, pp.1710-1713, 2003.
DOI : 10.1067/mcp.2003.1

S. Sanderson, J. Emery, and T. Baglin, Narrative Review: Aspirin Resistance and Its Clinical Implications, Annals of Internal Medicine, vol.142, issue.5, pp.370-80, 2005.
DOI : 10.7326/0003-4819-142-5-200503010-00012

A. Mendez, R. Herkolts, and A. Huber, Résistance à l'aspirine ? une entité complexe mais bien réelle, Curriculum Forum Med Schweiz, vol.6, pp.898-904, 2006.

J. Hung, J. Lam, L. Lacoste, and G. Letchacovski, Cigarette Smoking Acutely Increases Platelet Thrombus Formation in Patients With Coronary Artery Disease Taking Aspirin, Circulation, vol.92, issue.9, pp.2432-2436, 1995.
DOI : 10.1161/01.CIR.92.9.2432

P. Tuppin, A. Neumann, and N. Danchin, Evidence-based pharmacotherapy after myocardial infarction in France: Adherence-associated factors and relationship with 30-month mortality and rehospitalization, Archives of Cardiovascular Diseases, vol.103, issue.6-7, pp.6-7365, 2010.
DOI : 10.1016/j.acvd.2010.05.003

P. Ho, J. Spertus, F. Masoudi, K. Reid, and E. Peterson, Impact of Medication Therapy Discontinuation on Mortality After Myocardial Infarction, Archives of Internal Medicine, vol.166, issue.17, pp.1842-1849, 2006.
DOI : 10.1001/archinte.166.17.1842

R. Rossini, D. Capodanno, C. Lettieri, G. Musumeci, and T. Nijarazde, Prevalence, Predictors, and Long-Term Prognosis of Premature Discontinuation of Oral Antiplatelet Therapy After Drug Eluting Stent Implantation, The American Journal of Cardiology, vol.107, issue.2, pp.186-194, 2011.
DOI : 10.1016/j.amjcard.2010.08.067

D. Legrand and V. Legrand, Adhésion thérapeutique aux antiagrégants chez le patient coronarien, Rev Med Liège, vol.65, pp.304-310, 2010.

N. Col, J. Fanale, and P. Kronholm, The Role of Medication Noncompliance and Adverse Drug Reactions in Hospitalizations of the Elderly, Archives of Internal Medicine, vol.150, issue.4, pp.841-845, 1990.
DOI : 10.1001/archinte.1990.00390160093019

E. Vermeire, J. Wens, P. Van-royen, Y. Biot, and H. Hearnshaw, Interventions for improving adherence to treatment recommendations in people with type 2 diabetes mellitus, Cochrane Database Syst Rev, vol.18, p.3638, 2005.

J. Kiechel, Galénique et observance: de la technologie à la biologie. Labo Pharma, Probl Tech, vol.30, issue.324, 1982.

C. Tarquinio and F. Guillemin, Développement de l'Echelle Générale Observance pour Maladies Chroniques « EGOMAC », travail de l'Unité APEMAC en cours de finalisation et de validation

. Traités-hippocratiques and . Préceptes, De la Bienséance, p.1855

H. Autorité and D. Santé, Commission de la Transparence, pp.160-300

S. Lacaille, Observance des traitements médicamenteux [thèse], 2002.

L. Auvrey and C. Sermet, Consommations et prescriptions pharmaceutiques chez les personnes ??g??es, G??rontologie et soci??t??, vol.25, issue.4, pp.13-27, 2002.
DOI : 10.3917/gs.103.0013

D. De-lapouge, Formes pharmaceutiques orales et observance, Thèse de doctorat d'état des sciences pharmaceutiques, 1982.

D. Richard, D. Lapouge, and D. , Les formes médicamenteuses par voie orale. Impact Médecin Hebdo, dossier n°196, pp.1-14, 1988.

A. Becteuck, P. Calop, J. Loyer, and S. , Culture pharmaceutique, Perception du traitement médicamenteux et difficulté de consommation des médicaments chez le sujet âgé, Journal de la pharmacie clinique, vol.20, issue.2, pp.110-113, 2001.